ERBB2 and neoplasm: Trastuzumab emtansine is indicated for patients with residual HER2-positive tumor cells after neoadjuvant treatment, and its warning is related to hepatoxicity, cardiotoxicity, and embryotoxicity (Poon et al., 2013; von Minckwitz et al., 2019).